Laekna Inc. (2105)

Overview

Laekna, Inc. is an investment holding company deeply involved in the life sciences sector with a focus on developing and bringing to market therapies aimed at cancer and liver diseases on a global scale. Since its inception in 2016, the company has positioned itself as a pivotal player in the healthcare industry, leveraging advanced scientific research methods to tackle some of the most challenging medical conditions. Located in Shanghai, China, Laekna continues to expand its influence worldwide through its innovative approach to drug development and commercialization.

Products and Services

• LAE002: A competitive inhibitor of adenosine triphosphate (ATP) aimed at targeting the AKT pathway for the treatment of various cancers including ovarian, prostate, and breast cancers, as well as PD-1/PD-L1 drug-resistant solid tumors. This highlights Laekna's focus on addressing hard-to-treat malignancies through targeted therapy.
• LAE001: An androgen synthesis inhibitor that works by inhibiting specific enzymes (cytochrome P450 family 17 subfamily A member 1 and cytochrome P450 family 11 subfamily B member 2), used in the treatment of prostate cancer. This approach represents the company's commitment to hormonal therapies in cancer treatment.
• LAE005: A ligand-blocking humanized anti-PD-L1 IgG4 antibody. This product is part of Laekna's strategy to enhance the immune system's ability to fight cancer by blocking a pathway that tumors use to evade detection.
• LAE003: Targeted for treating hereditary hemorrhagic telangiectasia and proteus syndrome, showcasing Laekna's interest in rare diseases alongside its work on more prevalent conditions.
• LAE102: A potent and selective monoclonal antibody against activin receptor type IIA for use in cancer treatment. It represents the company's efforts in developing biologics that interfere with cancer growth signalling pathways.
• LAE105: Aimed at treating liver fibrosis through the depletion of activated hepatic stellate cells. This method underlines Laekna's dedication to combating liver disease, a major health issue worldwide.
• Inhibitory Receptors and Ligands/Receptors Development: Laekna is also focusing on inhibitory receptors (LAE109, LAE111, LAE113, and LAE117) expressed by cancer infiltrating lymphocytes, and ligands/receptors (LAE112) expressed on or produced by cancer cells. This area of research is crucial for understanding and developing new strategies to enable the immune system's fight against cancer.
• Liver Fibrosis and Cancer Drug Candidates: The development of additional liver fibrosis (LAE104 and LAE106) and cancer (LAE118, LAE119, and LAE120) drug candidates further illustrates the broad spectrum of Laekna's research and development activities aimed at addressing a wide range of serious health conditions.